Ratings Pfizer Limited

Equities

PFIZER

INE182A01018

Delayed NSE India S.E. Other stock markets 02:05:37 09/05/2024 pm IST			5-day change	1st Jan Change
4,300 ^INR	+0.49%		+0.54%	+0.73%

25/04	Pfizer Limited Receives Order from Deputy Commissioner, Dehradun - Sector 8: Uttarakhand	CI
02/04	Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
With an expected P/E ratio at 39.02 and 33.32 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PFIZER LIMITED	+0.73%	2.35B	B-
ELI LILLY AND COMPANY	+32.95%	698B	C+
NOVO NORDISK A/S	+26.51%	568B	B
JOHNSON & JOHNSON	-4.97%	358B	C+
MERCK & CO., INC.	+18.83%	328B	B-
ABBVIE INC.	+3.54%	283B	C+
ASTRAZENECA PLC	+15.91%	238B	B+
NOVARTIS AG	+6.68%	203B	B-
ROCHE HOLDING AG	-9.08%	198B	A+
AMGEN INC.	+6.70%	165B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes